SCHEDULE: Balyasny Asset Management Boosts Verastem Stake

Balyasny Asset Management and its affiliates report a 9.99% beneficial ownership stake in Verastem Inc., including shares from exercisable warrants.

Summary

• Balyasny Asset Management L.P. and its related entities (BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny) collectively hold a 9.99% beneficial ownership stake in Verastem Inc.
• This stake amounts to 5,777,396 shares of Common Stock.
• The reported shares include 1,571,428 shares issuable upon the exercise of warrants.
• The ownership percentage is based on 54,949,170 shares outstanding as of May 12, 2025, as reported in Verastem Inc.'s Quarterly Report on Form 10-K filed on May 13, 2025.
• A 9.99% beneficial ownership blocker prevents the reporting persons from exercising warrants if it would cause their ownership to exceed this threshold, meaning they cannot currently exercise all held warrants.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Verastem Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant, stable institutional ownership stake, which is generally a positive signal of investor confidence. The 9.99% blocker is a standard practice for passive investors to avoid triggering additional regulatory burdens, not necessarily a negative. It's a neutral-to-positive update on ownership structure.

Positives

• Significant institutional investor, Balyasny Asset Management, maintains a substantial stake, indicating continued interest in Verastem Inc.
• The holding includes a significant portion of shares from exercisable warrants, suggesting a potential long-term view or strategic position.

Negatives

• The 9.99% beneficial ownership blocker prevents the full exercise of all warrants held by the reporting persons, limiting their immediate upside from warrant conversion beyond this threshold.

Risks

• The 9.99% beneficial ownership blocker restricts the reporting persons from increasing their stake beyond this percentage through warrant exercise, potentially limiting their influence or further investment in the company.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in Verastem Inc., a biotechnology company. Large passive stakes by investment managers like Balyasny Asset Management can signal confidence in the company's long-term prospects within the competitive biotechnology sector, particularly given the inclusion of warrants.

Comparison to Industry Standards

• A 9.99% stake is a significant passive position for an institutional investor in a publicly traded biotechnology company, often signaling a long-term investment horizon rather than an activist intent.
• The use of a 9.99% blocker is a common strategy for institutional investors to avoid triggering certain beneficial ownership reporting requirements or control-related regulations that apply at or above 10% ownership.
• Compared to other biotech companies, a substantial institutional holding like this can be viewed positively, as it suggests a professional assessment of the company's value proposition.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially reinforcing confidence in the stock due to a large, passive investment by a reputable firm.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a significant passive ownership stake by Balyasny Asset Management. It indicates a continued, stable institutional presence in Verastem Inc. at the 9.99% threshold, which is a common practice for large investors to avoid triggering additional regulatory requirements. There are no new material financial results, strategic shifts, or operational updates that would warrant a change in investment thesis based solely on this filing. Therefore, a 'hold' recommendation is appropriate as it confirms existing institutional interest without providing new catalysts for a 'buy' or 'sell' decision.

Keywords

Verastem Inc., Balyasny Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Biotechnology, Healthcare